Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ: OMER )

7.060 +0.090 (+1.29%)
Streaming Delayed Price Updated: 12:22 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 86,482
Open 6.950
Bid (Size) 7.050 (4)
Ask (Size) 7.070 (4)
Prev. Close 6.970
Today's Range 6.829 - 7.140
52wk Range 2.965 - 13.60
Shares Outstanding 62,855,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
From Omeros Corporation
Via Business Wire

Performance

YTD
-28.25%
-28.25%
1 Month
-21.73%
-21.73%
3 Month
-24.00%
-24.00%
6 Month
+70.94%
+70.94%
1 Year
+128.48%
+128.48%

More News

Read More
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
From Omeros Corporation
Via Business Wire
What's Next: Omeros's Earnings Preview
Via Benzinga
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
From Omeros Corporation
Via Business Wire
Earnings Scheduled For March 31, 2025
Via Benzinga
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings
Via Benzinga
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
From Omeros Corporation
Via Business Wire
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
From Omeros Corporation
Via Business Wire
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
From Omeros Corporation
Via Business Wire
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
From Omeros Corporation
Via Business Wire
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
From Omeros Corporation
Via Business Wire
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
From Omeros Corporation
Via Business Wire
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
From Omeros Corporation
Via Business Wire
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline
Via Benzinga
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
Via Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
From Omeros Corporation
Via Business Wire
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.